GENMAB (GENMAB) News
Follow GENMAB (GENMAB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Genmab reports positive Phase 3 results for three cancer treatments
Genmab reported positive Phase 3 results for three cancer treatments.
EQUITY | Oct 28, 2026, 05:29 PM UTC
M
Genmab Reports Positive Interim Results for Petosemtamab Combination
Genmab said the combination showed statistically significant, clinically meaningful improvement in overall survival and objective response in first-line patients with recurrent or metastatic PD-L1-positive head and neck
EQUITY | Oct 28, 2026, 01:40 PM UTC
M
Genmab Reports Significant Survival and Response Improvement in Interim Cancer Analysis
Genmab reported statistically significant, clinically meaningful improvement in overall survival and objective response with petosemtamab combination at the first interim analysis in first-line recurrent or metastatic PD
EQUITY | Oct 28, 2026, 01:40 PM UTC
L
Genmab Reports 28.2-Month Median Overall Survival in Phase 2 Study
Genmab reported median overall survival of 28.2 months with petosemtamab plus pembrolizumab in a Phase 2 study.
EQUITY | Oct 26, 2026, 11:08 AM UTC